• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

    1.130 -0.070 (-5.83%)
    Streaming Delayed Price Updated: 10:47 AM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Estrella Immunopharma, Inc. - Common Stock

    BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
    Via Investor Brand Network
    News headline image
    Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
    From Estrella Immunopharma
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
    From Estrella Immunopharma, Inc.
    Via Business Wire
    BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination
    Via Investor Brand Network
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.